Katherine A. High

CIK: 0001631248

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

INCY

INCYTE CORP

Director

CRSP

CRISPR Therapeutics AG

Director

Discretionary Trading P&L

Holdings

Transaction History (4 total)

INCY
INCYTE CORP
Jun 8, 2026
Award(A)
Direct
1.6K shares-
CRSP
CRISPR Therapeutics AG
Jun 5, 2026
Award(A)
Stock Option (Right to Buy)
Direct
13K shares-
INCY
INCYTE CORP
Jun 10, 2025
Award(A)
Direct
2.5K shares-
CRSP
CRISPR Therapeutics AG
Jun 5, 2025
Award(A)
Stock Option (Right to Buy)
Direct
13K shares-

		Type	Shares	Price		Ownership
Jun 8, 2026	INCY INCYTE CORP	Award(A)	1,642	-	$0	Direct
Jun 5, 2026	CRSP CRISPR Therapeutics AG	Award(A) Stock Option (Right to Buy)	13,000	-	-	Direct
Jun 10, 2025	INCY INCYTE CORP	Award(A)	2,518	-	-	Direct
Jun 5, 2025	CRSP CRISPR Therapeutics AG	Award(A) Stock Option (Right to Buy)	13,000	-	-	Direct

1-4 of 4 transactions

About High Katherine A

High Katherine A (SEC CIK 0001631248) files insider reports with the SEC as Director of INCYTE CORP (INCY) and Director of CRISPR Therapeutics AG (CRSP).

Signal8 holds 4 ownership filings by High Katherine A, all Form 4s, filed between Jun 6, 2025 and Jun 10, 2026. Those filings report 4 transactions, from Jun 5, 2025 to Jun 8, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on High Katherine A's filings is in BOSTON, MA.

Recent filings by High Katherine A

Jun 8, 2026: Grant or award of INCY shares (Form 4, code A).
Jun 5, 2026: Grant or award of CRSP derivative securities (Form 4, code A).
Jun 10, 2025: Grant or award of INCY shares (Form 4, code A).
Jun 5, 2025: Grant or award of CRSP derivative securities (Form 4, code A).

Other insiders filing for INCYTE CORP (INCY)

CAGNONI PABLO J, President, Global Head of R&D
Heeson Lee, EVP, Head of Incyte Intl
BAKER BROS. ADVISORS LP, Director
Clancy Paul J, Director
HARRIGAN EDMUND, Director
Gardner David H, EVP, Chief Strategy Officer

How to read Form 4 transaction codes